FAM (5-fluorouracil, doxorubicin, and mitomycin) plus triazinate (FAM-T) in gastric carcinoma: a combined phase II trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization

Cancer Treat Rep. 1987 Apr;71(4):419-20.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Clinical Trials as Topic
  • Doxorubicin / administration & dosage
  • Drug Administration Schedule
  • Drug Evaluation
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Male
  • Middle Aged
  • Mitomycin
  • Mitomycins / administration & dosage
  • Stomach Neoplasms / drug therapy*
  • Triazines / administration & dosage

Substances

  • Mitomycins
  • Triazines
  • Mitomycin
  • Doxorubicin
  • triazinate
  • Fluorouracil

Supplementary concepts

  • FAM protocol